Acute myeloid leukemia remains one of the most challenging blood cancers to treat, largely because cancer stem cells hide among healthy bone marrow cells, making targeted destruction nearly impossible without collateral damage. This therapeutic dilemma has stymied efforts to adapt the revolutionary CAR-T cell approach that has transformed lymphoma treatment for this aggressive leukemia type.
Scientists have identified CD96, a surface protein present in nearly half of acute myeloid leukemia cases, as a potential breakthrough target. The protein appears preferentially on leukemia stem cells rather than the more mature cancer blasts, while remaining conspicuously absent from normal blood-forming stem cells. This selective expression pattern creates a therapeutic window that researchers engineered into modified immune cells called CAR-T cells, which demonstrated potent anti-leukemia activity correlated directly with CD96 levels on cancer cells.
The most promising configuration incorporated CD28 signaling domains, enhancing both the proliferation and killing capacity of the engineered immune cells. In laboratory models, these CD96-targeted cells eliminated high-expressing leukemia while preserving normal blood cell production—a critical safety consideration. For cases with lower CD96 expression, combining this approach with CD33-targeted immune enhancers broadened the therapeutic reach without compromising specificity.
This represents a meaningful advance in precision leukemia immunotherapy, addressing the fundamental challenge of distinguishing cancer stem cells from their healthy counterparts. While promising, the approach requires validation in human trials to confirm both efficacy and the crucial preservation of normal blood cell function during treatment.